腹膜透析相关感染防治实践的区域差异:PDOPPS研究
结果显示各国在导管置入时抗生素使用、出口处预防策略及经验性腹膜炎治疗方面存在显著差异,且对ISPD指南推荐的采纳有限。
要点
- 导管置入时预防性抗生素使用比例美国最低(63%),加拿大和英国最高(100%)。
- 出口处预防策略差异大:日本(4%)和泰国(28%)使用率最低,美国常用氨基糖苷类(72%)。
- 经验性革兰阳性菌腹膜炎治疗中万古霉素使用英国(88%)和美国(83%)最高,其他地区仅10-45%。
核心结论
- 各国腹膜透析相关感染的预防和治疗策略存在差异,且对ISPD指南推荐的采纳有限。
研究设计与样本
- PDOPPS为前瞻性队列研究,纳入澳大利亚/新西兰、加拿大、泰国、日本、英国和美国全国代表性PD患者样本,通过医疗主任问卷调查获取各中心感染防治实践数据。
主要发现
- 导管置入时抗生素使用比例美国最低(63%),加拿大和英国最高(100%)。
- 出口处抗菌预防使用率日本最低(4%),泰国次低(28%)。
- 出口处莫匹罗星是澳新(56%)、加拿大(50%)和英国(47%)的主要预防策略,美国更常用氨基糖苷类(72%)。
- 经验性革兰阳性菌腹膜炎治疗中万古霉素使用英国(88%)和美国(83%)最高,其他地区10-45%;革兰阴性菌经验性氨基糖苷类治疗澳新(72%)和英国(77%)最高,其他地区10-45%。
临床怎么用
- 临床实践中应关注本国与ISPD指南推荐的差距,优化PD相关感染的预防和治疗策略。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peritoneal dialysis (PD)-related infections lead to significant morbidity. The International Society for Peritoneal Dialysis (ISPD) guidelines for the prevention and treatment of PD-related infections are based on variable evidence. We describe practice patterns across facilities participating in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). METHODS: PDOPPS, a prospective cohort study, enrolled nationally representative samples of PD patients in Australia/New Zealand (ANZ), Canada, Thailand, Japan, the UK and the USA. Data on PD-related infection prevention and treatment practices across facilities were obtained from a survey of medical directors'. RESULTS: A total of 170 centers, caring for >11 000 patients, were included. The proportion of facilities reporting antibiotic administration at the time of PD catheter insertion was lowest in the USA (63%) and highest in Canada and the UK (100%). Exit-site antimicrobial prophylaxis was variably used across countries, with Japan (4%) and Thailand (28%) having the lowest proportions. Exit-site mupirocin was the predominant exit-site prophylactic strategy in ANZ (56%), Canada (50%) and the UK (47%), while exit-site aminoglycosides were more common in the USA (72%). Empiric Gram-positive peritonitis treatment with vancomycin was most common in the UK (88%) and USA (83%) compared with 10-45% elsewhere. Empiric Gram-negative peritonitis treatment with aminoglycoside therapy was highest in ANZ (72%) and the UK (77%) compared with 10-45% elsewhere. CONCLUSIONS: Variation in PD-related infection prevention and treatment strategies exist across countries with limited uptake of ISPD guideline recommendations. Further work will aim to understand the impact these differences have on the wide variation in infection risk between facilities and other clinically relevant PD outcomes.
引用
- Boudville N, Johnson DW, Zhao J, et al. Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2019. PMID: 30053214. doi:10.1093/ndt/gfy204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。